EndoChoice said that its GI diagnostics division offers the broad range of diagnostic products and services in the industry, including anatomic pathology services, immunochemical fecal occult blood tests (FIT), H pylori tests, and the first gene expression tests for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). EndoChoice Pathology provides lab services through its gastrointestinal specific and subspecialty- trained pathologists.

Mark Gilreath, CEO of EndoChoice, said: “Our unique ability to provide a comprehensive suite of diagnostic products and services is important to our customers and their patients. This successful acquisition further expands our ability to deliver outstanding clinical services to our physician clients across the nation.”

Dr Smith said: “We are excited to leverage our GI expertise and join the EndoChoice team. For pathology services, our subspecialty focus ensures quality results. With its complete focus on the GI community, EndoChoice is a natural fit for our organization.”

EndoChoice designs, manufactures and markets solutions for professionals in gastrointestinal endoscopy worldwide.

Founded in 1989, Pathworks is a College of American Pathologists (CAP) accredited national reference laboratory located in Atlanta, GA.